Reply to: Treatment Intensification Based on Residual Disease in Elderly Patients With AML ...
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3 ...
Efficacy of 177Lu-PSMA-617 with or without ARPIs for the treatment of mCRPC: VISION secondary analysis. Safety profile of lutetium-177 in patients with impaired renal function: A retrospective ...
Where Is the Future of Adjuvant Therapy for Hepatocellular Carcinoma? The following represents disclosure information provided by authors of this manuscript. All relationships are considered ...
The article by Biller et al entitled “Comparison of PREMM5 and PREMMplus Risk Assessment Models to Identify Lynch Syndrome” (JCO Precision Oncology 10.1200/PO-24 ...
Addressing Bias in Feature Importance: A Hybrid Approach for Risk Prediction in Prognostic Survival Models ...
We created an annotated corpus of tumor morphology and topography mentions consisting of 1,101 documents. We combined it with the CANTEMIST corpus (Cancer Text Mining Shared Task). Specifically, we ...
P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-50 years with intermediate and poor-risk metastatic germ cell ...
Real world effectiveness of systemic treatment in patients (pts) with advanced upper tract urothelial carcinoma (UTUC) with histological variants. This is an ASCO Meeting Abstract from the 2025 ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback